AU
UK
CA
NZ
IND
US
Akebia Therapeutics reported first-quarter 2026 net product revenue of $15.8 million for Vafseo (vadadustat), its oral hypoxia-inducibleFactorprolyl hydroxylase inhibitor for the treatment of anaemia associated with chronic kidney disease, alongside a 60% sequential increase in patient numbers. The commercial metrics represent genuine early momentum. …
Apyx Medical delivered a first-quarter performance that combined revenue outperformance,Marginimprovement, and guidance upgrade — the trifecta most likely to drive a meaningful re-rating in a small-cap medical technology company. Shares closed up 22% at $3.56, a move that reflects the market's positive reassessment of …
Key Highlights
Introduction: A Rare Disease Catalyst That Changes the Regulatory Narrative
An Unmet Need That Commands Attention
Ovarian Cancer and the Search for Effective Cellular Combinations
Why Reimbursement Infrastructure Is a Critical Commercial Inflection
A Rare Disease Setting Where Clinical Nuance Drives Valuation
A Commercial-StageMedTechWith Accelerating Revenue Growth
Key Highlights
Please wait processing your request...